CD274 and cancer: While PD-L1 expression is not yet used in HCC to determine eligibility for immunotherapies, Food and Drug Administration (FDA) approvals for immune checkpoint inhibitor therapy are linked to specific levels of PD-L1 expression for several other cancers including non-small-cell lung cancer and bladder cancer [45].